Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05710887CT.gov N2O for Acute Suicidality and Depression in the ED | — | Withdrawn | — | — | — |
NCT07262008CT.gov Sustained Mood Improvement With Laughing Gas Exposure | — | Not Yet Recruiting | — | — | — |
NCT05528718CT.gov SMILE Trial - Imaging Sub-Study | — | Completed | — | — | — |
NCT04957368CT.gov Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial | — | Completed | — | — | — |
NCT05357040CT.gov Antidepressant Effects of Nitrous Oxide | — | Withdrawn | — | — | — |
NCT04199143CT.gov Brain Reactivity to Nitrous Oxyde in Depression : an MRI and Ultrasound Study (PROTOBRAIN Pilote) | — | Completed | — | — | — |
NCT03932825CT.gov Nitrous Oxide for Major Depressive Disorder | — | Completed | — | — | — |
NCT03869736CT.gov Nitrous Oxide for the Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT03736538CT.gov Nitrous Oxide- Suicidal Ideation | — | Enrolling By Invitation | — | — | — |
NCT02994433CT.gov NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits | — | Recruiting | — | — | — |
Show 2 more trialsShow fewer
NCT03283670CT.gov Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies | — | Completed | — | — | — |
NCT02139540CT.gov Nitrous Oxide as Treatment for Major Depression - a Pilot Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dinitrogen Monoxide (this asset) | University of Chicago | Approved | BB · 67 |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | Massachusetts General Hospital | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Dinitrogen Monoxide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy | — | P4 | BB · 69 |
| Neurofibromatosis | — | P4 | BB · 69 |
| Hydrocephalus | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dinitrogen Monoxide in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dinitrogen-monoxide-major-depressive-disorder-15605
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →